EPRX Eupraxia Pharmaceuticals Inc.
Company Analysis
Latest News
🔴 Eupraxia Pharmaceuticals is trading 5.16% down today with no clear company-specific catalyst identified
Eupraxia Pharmaceuticals is trading at $6.98, down -5.16%, after no clear company-specific catalyst was identified for August 28, 2026. • No reliable August...
🟢 Eupraxia Pharmaceuticals is trading 5.92% up in pre-market with no clear catalyst identified
Eupraxia Pharmaceuticals is trading 5.92% up in pre-market at $7.87, after rising from the August 26 close of $7.43, with no clear catalyst identified. - No...
🟢 Eupraxia Pharmaceuticals is trading 6.54% up today
Eupraxia Pharmaceuticals is trading 6.54% up at $7.17 based on the provided live price; the catalyst remains unconfirmed. - No new company-specific...
🟢 Eupraxia Pharmaceuticals is trading 12.33% up in pre-market — catalyst remains unconfirmed
Eupraxia Pharmaceuticals is trading 12.33% up at $7.56 in pre-market, based on the provided pre-market price versus the August 21, 2026 close of $6.73; the...
🔴 Eupraxia Pharmaceuticals is trading 7.88% down in pre-market with no company-specific catalyst identified
Eupraxia Pharmaceuticals is trading 7.88% down in pre-market at $6.20, with no confirmed company-specific catalyst identified. - The decline follows the...
🔴 Eupraxia Pharmaceuticals is trading 5% down in after-hours trading with no confirmed catalyst
Eupraxia Pharmaceuticals is trading 5.19% down in after-hours trading at $6.38, after falling from the August 21 regular-session close of $6.73; the catalyst...
🟢 Eupraxia Pharmaceuticals is trading 12.33% up in after-hours trading as Nasdaq Composite gains 1.24%
Eupraxia Pharmaceuticals is trading 12.33% up at $7.56 amid broader risk-on sentiment, with major U.S. indices finishing higher. - It closed at $6.73 on...
🟢 Eupraxia Pharmaceuticals is trading 10% up in after-hours trading amid broader risk-on sentiment
Eupraxia Pharmaceuticals is trading at $7.40, up 9.96% after closing at $6.73 on August 21, 2026, with the advance appearing most consistent with broader...
🟢 Eupraxia Pharmaceuticals is trading 12% up today in pre-market despite no clear overnight company-specific announcement
Eupraxia Pharmaceuticals is trading 12.43% up at $7.60 after no clear company-specific announcement was identified overnight. - Recent company news includes...
🔴 Eupraxia Pharmaceuticals is trading 7.28% down today in pre-market — no clear company-specific catalyst identified
Eupraxia Pharmaceuticals is trading 7.28% down at $6.50, with no clear company-specific negative announcement, filing, earnings update, or analyst action...
🟢 Eupraxia Pharmaceuticals is trading 8.21% up in pre-market — no clear catalyst identified
Eupraxia Pharmaceuticals is trading 8.21% up at $7.38 in pre-market, with no clear company-specific catalyst identified. - Compared with its August 17, 2026...
🔴 Eupraxia Pharmaceuticals is trading 11.58% down in pre-market as global risk sentiment weakens
Eupraxia Pharmaceuticals is trading 11.58% down at $6.03, coinciding with weaker global risk sentiment. - Shares closed at $6.82 on August 17, 2026. - No new...
🟢 Eupraxia Pharmaceuticals is trading 10.85% up in after-hours trading after durable symptom improvement in RESOLVE trial
Eupraxia Pharmaceuticals is trading now 10.85% up at $7.56 after new RESOLVE trial data showed durable symptom improvement in eosinophilic esophagitis. -...
Eupraxia's Once-a-Year Throat Treatment Posts Strong Year-Long Data — But Can a $475 Million Biotech Crack a Market Dominated by Sanofi?
Shares of Eupraxia Pharmaceuticals surged 8.6% to $7.30 after new data from the company's mid-stage clinical trial showed its experimental injection for a...
🟢 Eupraxia Pharmaceuticals is trading 8.63% up in pre-market after positive RESOLVE trial findings
Eupraxia Pharmaceuticals is trading 8.63% up now at $7.30 after positive RESOLVE trial findings for EP-104GI in eosinophilic esophagitis. - Painful and...
Eupraxia Pharmaceuticals reports sustained relief, eliminates severe swallowing pain
Eupraxia Pharmaceuticals Inc. announced positive results from a new analysis of its Phase 1b/2a RESOLVE trial for EP-104GI. The study targeted Eosinophilic...
🟢 Eupraxia Pharmaceuticals is trading 6% up today after Q2 earnings beat
Eupraxia Pharmaceuticals is trading 5.71% up now at $6.85 after its August 11, 2026 second-quarter earnings beat. - The results were supported by a $133.6...
🟢 Eupraxia Pharmaceuticals is trading 13% up in pre-market after Q2 report highlighted $133.7 million liquidity
Eupraxia Pharmaceuticals is trading sharply higher at $7.30, up +12.65%, after its August 11 Q2 report highlighted $133.7 million in liquidity and cash runway...
🟢 Eupraxia Pharmaceuticals is trading 8% up today in pre-market after Q2 EPS beat
Eupraxia Pharmaceuticals is trading $7.00 (+8.02%) in pre-market after reporting Q2 EPS of $(0.23), beating the $(0.25) estimate. - Management reported $133.7...
🟢 Eupraxia Pharmaceuticals is trading 5% up in after-hours trading after Q2 EPS beat estimates
Eupraxia Pharmaceuticals is trading $6.82 (+5.25%) after second-quarter 2026 EPS of $(0.23) beat the $(0.25) consensus estimate. • Reported a $14.5 million...